Gensight Biologics SA Aktie
0,39 €
Deine Einschätzung
Gensight Biologics SA Aktie
Was spricht für und gegen Gensight Biologics SA in den nächsten Jahren?
Pro
Kontra
Rendite von Gensight Biologics SA im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Gensight Biologics SA | 0,65 % | 0,78 % | -14,60 % | -84,09 % | -12,19 % | -94,61 % | -80,84 % |
Celsion Corp. | -7,55 % | -25,68 % | 29,41 % | 3,77 % | 49,66 % | -91,94 % | - |
India Globalization Capital | -5,60 % | 9,26 % | 65,03 % | 69,78 % | 80,15 % | -58,74 % | -68,53 % |
CEL-SCI Corp. | -1,62 % | -8,92 % | -23,28 % | -43,80 % | -43,80 % | -89,68 % | - |
Kommentare
News
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
GenSight Biologics Announces its 2024 Financial Calendar
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal